Remove Defibrillator Remove Kidney Disease Remove Patient Care
article thumbnail

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices 

Cardiometabolic Health Congress

Staying informed about these cutting-edge developments is critical for providing exceptional patient care. Join us as we examine the landmark approvals that are revolutionizing patient outcomes. The label includes a “black box” warning for CV risk due to blood clots.

article thumbnail

Top 10 Cardiac Diagnosis Trends in 2024

GEMMS

These advancements, alongside software enhancements, enable early detection of cardiac diseases, empowering healthcare providers to make evidence-based decisions and tailor appropriate patient care plans. Genetic testing and DNA sequencing improve the accuracy of predicting heart disease risk.